These findings highlight the transition of CHI3L1 from a peripheral biomarker to a key player in CNS pathology, emphasizing its emerging significance as both a diagnostic biomarker and therapeutic target in various brain diseases. This evidence concerns the gene CHI3L1 and brain disorder.